Posted on January 29, 2015 by Sitemaster
A new article in the February 2015 of the Journal of Urology may actually tell us as much (or more) about the difficulties of relying on data from large, retrospective analyses of single institution data as it does about the actual issue references in the headline above. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: biochemical, inhibitor, PDE5, phosphdiesterase 5, recurrence, risk, surgery | 4 Comments »
Posted on May 25, 2011 by Sitemaster
According to media information released earlier today by Vivus, Inc., the company’s selective, investigational phosphodiesterase type 5 (PDE5) inhibitor known as avanafil has shown positive results in a randomized, double-blind, multi-center, placebo-controlled Phase III clinical trial for the treatment of erectile dysfunction (ED) in patients after a radical prostatectomy. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: avanafil, ED, erctile dysfunction, inhibitor, PDE5 | Leave a comment »
Posted on August 19, 2008 by Sitemaster
Recent publications reported on today include:
- Demonstration of the validity of the Epstein criteria in defining pathologically insignificant prostate cancer
- A review of the value of sildenafil (Viagra) and similar products in treatment of erectile dysfunction among prostate cancer patients
- A review of the significance of “gene fusion” and its relevance in prostate cancer … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: cancer, criteria, Epstein, fusion, gene, inhibitors, insignificant, news, PDE5, prostate, update | 4 Comments »